×
About 1,763 results

ALLMedicine™ Bullous Pemphigoid Center

Research & Reviews  641 results

Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids a...
https://doi.org/10.1007/s40257-022-00688-x 10.1111/bjd.20881
American Journal of Clinical Dermatology; Tsai YJ, Cho YT et. al.

May 18th, 2022 - Rituximab is a potential initial adjuvant therapy for bullous pemphigoid, yet clinical experience is scarce. We aimed to examine the clinical outcomes and safety of initial combination therapy with systemic corticosteroids and adjuvant rituximab f...

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
https://clinicaltrials.gov/ct2/show/NCT04612790

May 13th, 2022 - Bullous pemphigoid (BP) is a rare disease mainly affecting the elderly. BP is associated with significant morbidity and increased mortality secondary to increased risk of secondary infections, comorbid conditions, and serious side effects from hig...

Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primaril...
https://doi.org/10.1111/1346-8138.16428
The Journal of Dermatology; Takamura S, Teraki Y

May 12th, 2022 - We report a patient with bullous pemphigoid (BP) who was successfully treated with dupilumab monotherapy. To clarify the underlying mechanism of this effective treatment, we investigated the dynamics of a variety of cytokine-producing T cells befo...

Infantile bullous pemphigoid.
https://doi.org/10.1684/ejd.2022.4229
European Journal of Dermatology : EJD; Cozzani E, Herzum A et. al.

May 7th, 2022 - Infantile bullous pemphigoid.|2022|Cozzani E,Herzum A,Gasparini G,Viglizzo G,Parodi A,|drug therapy,

Journal club: Bullous pemphigoid.
https://doi.org/10.1684/ejd.2022.4211
European Journal of Dermatology : EJD; Rosell-Diaz A, Lefevre MA et. al.

May 7th, 2022 - Journal club: Bullous pemphigoid.|2022|Rosell-Diaz A,Lefevre MA,Mohme S,Alband N,Nogueira M,|

see more →

Drugs  2 results see all →

Clinicaltrials.gov  15 results

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
https://clinicaltrials.gov/ct2/show/NCT04612790

May 13th, 2022 - Bullous pemphigoid (BP) is a rare disease mainly affecting the elderly. BP is associated with significant morbidity and increased mortality secondary to increased risk of secondary infections, comorbid conditions, and serious side effects from hig...

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT01571895

Jan 18th, 2022 - The study will be a phase 2, multicentre, single arm, pilot study. It has been designed to determine if DF2156A has sufficient activity to warrant its further development. A total of twelve (12) BP patients will be involved, who will be administer...

A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT04499235

Jul 8th, 2021 - This is a randomized, double-blind, placebo-controlled study to assess the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP). Subjects will receive topical mometasone furoate cream (MFC) therapy concurre...

Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients
https://clinicaltrials.gov/ct2/show/NCT03129308

Aug 20th, 2019 - So far no systematic studies exist about the prevalence and incidence of autoimmune blistering disease (AIBD) in HIV infected patients. Various case reports have been published, though the overall frequency appears to be low. The aim of this proje...

Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT03926377

Apr 24th, 2019 - Glucocorticoids have direct effects on bone remodeling by suppressing bone formation (inhibition of osteoblastic differentiation, inhibition of mature osteoblasts function and apoptosis of mature osteoblasts) and by increasing bone resorption (dec...

see more →

News  42 results

Age, Skin Cancer Risks for ICI-Induced Bullous Pemphigoid
https://www.medscape.com/viewarticle/972516

Apr 21st, 2022 - Bullous pemphigoid, an immune-mediated condition chacterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs) that may result in treatment interruption or ce...

A Starter Guide to Immunofluorescence Testing in Dermatology
https://www.mdedge.com/dermatology/article/249292/dermatopathology/starter-guide-immunofluorescence-testing-dermatology
Margaret Maria Cocks, MD, PhD

Dec 1st, 2021 - Direct immunofluorescence (DIF) is the go-to diagnostic test when evaluating vesiculobullous eruptions, connective tissue disease, and vasculitis. This specialized test allows visualization of autoantibodies and their reaction products in the epid.

Pruritic blistering rash
https://www.mdedge.com/familymedicine/article/246860/dermatology/pruritic-blistering-rash
MDedge Family Medicine;

Sep 30th, 2021 - This patient was given a diagnosis of linear IgA bullous dermatosis (LABD) based on biopsy results. (Biopsy is extremely helpful in differentiating bullous disorders.

Blistering Eruptions, Including Bullous Pemphigoid, Seen After COVID Vaccine
https://www.medscape.com/viewarticle/955308

Jul 26th, 2021 - NEW YORK (Reuters Health) - SARS-CoV-2 mRNA vaccines may trigger subepidermal blistering eruptions, particularly bullous pemphigoid and most often in older adults, U.S. clinicians report. However, "given the risks of SARS-CoV-2 infection, the rari...

Nivolumab-Induced Granuloma Annulare
https://www.mdedge.com/dermatology/article/241652/autoimmune-diseases/nivolumab-induced-granuloma-annulare
Bilal Fawaz, MD, Analisa Halpern, MD

Jun 16th, 2021 - Granuloma annulare (GA) is a benign, cutaneous, granulomatous disease of unclear etiology. Typically, GA presents in young adults as asymptomatic, annular, flesh-colored to pink papules and plaques, commonly on the upper and lower extremities.

see more →

Patient Education  5 results see all →